• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 6, 2013

View Archived Issues

Keryx’s Zerenex Phase II Wows; Expanded CKD Sales in Reach?

Keryx Biopharmaceuticals Inc.’s Zerenex (ferric citrate) may be poised to become the first oral iron booster that also provides phosphorous control in chronic kidney disease (CKD) patients, if new top-line data from a Phase II trial hold up. Read More

Big Pharma Deal Dynamics Move to Center Stage

VIENNA – Astrazeneca plc’s Marc Dunoyer made his scheduled appearance at a plenary session on transformational dealmaking during day two of the BIO-Europe 2013 meeting here at the Messe Wien Exhibition & Congress Center. Read More

Endo Acquires Paladin for $1.6B in Stock, Cash

Shares of Paladin Labs Inc. soared 49.4 percent Tuesday on news of an acquisition by Endo Health Solutions for $1 .6 billion in stock and cash. The merger will marry Paladin’s pipeline of products in attention deficit hyperactivity disorder, pain, urology and allergy with Endo’s health care assets under a newly formed entity based in Ireland, led by Endo’s management team. Read More

Pediatric ODAC Panel Wrestles with New Cancer Paradigm

All the hurdles in developing drugs to fight cancer in children came to the fore this week as the Pediatric Oncology Subcommittee of the FDA’s Oncology Drugs Advisory Committee (ODAC) grappled with the unknowns of science and a pressing unmet need as they discussed global pediatric development plans for Bristol-Myers Squibb Co.’s (BMS) nivolumab, Merck Sharp and Dohme’s MK-3475 and Novartis Pharmaceuticals Corp.’s LEE011. Read More

Cytori Shares Spike on Potential $531M Cell Therapy Deal

Cytori Therapeutics Inc. shares (NASDAQ:CYTX) headed skyward Tuesday morning after the company disclosed a deal with Chinese firm Lorem Vascular to commercialize Cytori cell therapy in the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia. Read More

Midatech’s Nanoparticle Platform Strikes ‘Gold’ in $16M Venture Round

LONDON – Midatech Ltd. is poised to move its gold nanoparticle delivery technology into Phase II after raising £10 million (US$16 million) in its first formal round, and attracting Ippon Capital SA as a new investor with a commitment of £7.6 million. Read More

Dual Peptide Could ‘Transform’ Diabetes Treatment, Study Shows

LONDON – A composite molecule that targets the two primary hormones that are released by the gut following meals can reduce weight and lower blood sugar in animal models, raising hopes of new and more effective treatments for obesity and diabetes. Read More

Other News To Note

• SRI International, of Menlo Park, Calif., said it was awarded a five-year contract valued up to $9.75 million from the National Institute on Drug Abuse to conduct preclinical safety studies of potential new medicines to treat substance abuse. Read More

Stock Movers

Read More

Clinic Roundup

• Cel-Sci Corp., of Vienna, Va., said a second interim review of the safety data from its open-label, randomized, Phase III study of immunotherapy candidate Multikine (leukocyte interleukin, injection) was conducted, with the independent data monitoring board recommending that the study continue unmodified. Read More

Earnings Roundup

• Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., posted U.S. net sales of ophthalmic drug Eylea (aflibercept) of $363 million for the third quarter, a 49 percent jump over the same period last year and topping consensus estimates of $350 million. Read More

Pharma: Clinic Roundup

• Shire plc, of Dublin, reported positive top-line results from two identically designed randomized placebo-controlled Phase III studies evaluating the efficacy and safety of Vyvanse (lisdexamfetamine dimesylate) capsules (CII) vs. placebo in adults with binge eating disorder (BED). Read More

Pharma: Other News To Note

• Pfizer Inc., of New York, said the FDA approved a prior approval supplement for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules CII. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe